Researchers found a small but greater risk of a hip fracture after 2 years of taking a "drug holiday" — stopping therapy — after long-term (≥ 3-year) use of one bisphosphonate, risedronate, versus ...

Adults with overweight or obesity, but not type 2 diabetes, lost 14.9% of their body weight after 46 weeks of receiving BI 456906, a novel glucagon/GLP-1 receptor agonist, during a phase 2 clinical ...